The effect of neoadjuvant chemotherapy on the perioperative morbidity of patients undergoing radical cystectomy for bladder cancer

Georgios Ioannis Papadopoulos, Charalampos Fragkoulis, Ioannis Glykas, Kimon Tsirkas, Konstantinos Stasinopoulos, Georgios Stathouros, Konstantinos Ntoumas


Introduction: Radical cystectomy (RC) with concurrent lymph node dissection is the treatment choice in muscle invasive bladder cancer (MIBC). The use of neoadjuvant chemotherapy (NAC) in patients with MIBC who will undergo RC appears to improve 5-year survival by 5% without affecting the perioperative morbidity of patients. The aim of this study is to present the effect of NAC on perioperative morbidity in patients undergoing RC in our department.

Material and Methods: A retrospective study of the data of patients undergoing radical cystectomy for MIBC was performed in our department regarding the years 2016 and 2017. Patients were divided into two groups depending on whether they received NAC or not. Afterwards, a comparison of the perioperative morbidity between the 2 groups was performed as expressed by the duration of surgery, the time of hospitalization, the occurrence of complications and the need for immediate re-intervention.

Results: Patients who underwent NAC were younger in a statistical significant way. On the other hand, there was no statistically significant difference between the two groups regarding the duration of surgery, the time of hospitalization, the need for reoperation, the appearance of wound infection, the occurrence of urinary tract infection, the need for transfusion, the appearance of deep vein thrombosis or the occurrence of complications from the cardiovascular and respiratory system.


neoadjuvant chemotherapy; bladder cancer; radical cystectomy

Full Text:



Abdollah F, Gandaglia G, Thuret R, et al. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: A trend analysis. Cancer Epidemiol 2013; 37(3): 219-25.

Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 2001;19(3): 666-75.

Stenzl A, Cowan NC, De Santis M, et al. Treatment of muscle invasive and metastatic bladder cancer: Update of the EAU Guidelines. Eur Urol 2011; 59(6): 1009-1018.

Winquist E, Kirchner TS, Segal R, et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: A systematic review and meta-analysis. J Urol 2004; 171:561-569.

Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349(9): 859-866.

David KA, Milowsky MI, Richney J, et al. Low incidence of perioperative chemotherapy for stage 3 bladder cancer 1998 to 2003: A report from the national cancer data base. J Urol 2007; 178(2): 451-454.

Bassi P, Ferrante GD, Piazza N, et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: A retrospective study of a homogeneous patient cohort. J Urol 1999;161(5): 1494-7.

Johnson D, Nielsen M, Matthews J, et al. Neoadjuvant Chemotherapy for Bladder Cancer Does Not Increase Risk of Periperative Morbidity. J Urol 2014; 114(2): 221-228.

Millican R, Dinney C, Swanson D, et al. Integrated therapy for locally advanced bladder cancer: Final report of a randomised trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 2001; 19(20): 4005-4013.

Sternberg CN, Bellnut J, Sonpavde G, et al. ICUD-EAU international consultation on bladder cancer 2012. l 2013; 63(1): 58-66.

Von der Maase H, Sengelov L, Roberts JT, et al. Long term survival results of a randomized trial comparing gemcitavine plus cisplatin with MVAC in patients with bladder cancer. J Clin Oncol 2005; 23(21): 4602-4608.

Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006; 107(3): 506-513.

Alva AS, Tallman CT, HE C, et al. Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle invansive bladder cancer: A multidisciplinary approach. Cancer 2012; 118(1): 44-53.

Johar RS, Hayn MH, Stegemann AP, et al. Complications after robot-assisted radical cystectomy: Results from the international robotic cystectomy consortium. Eur Urol 2013; 64(1): 52-57.

Gandaglia G, Popa I, Abdollah F, et al. The Effect of Neoadjuvant Chemotherapy on Perioperative Outcomes in Patients Who Have Bladder Cancer Treated with Radical Cystectomy: A Population-based Study. Eur Urol 2014;66(3): 561-568.